A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification

The study used a mixed-methods, retrospective design based on an online survey of people who received ibogaine detoxification for chronic opioid use at a single clinic in Mexico between 2012 and 2015. The analysed sample comprised 73 participants. The researchers collected quantitative data using a modified version of a ‘‘persisting effects of ibogaine’’ questionnaire and a set of open-ended questions about personal changes, greatest benefits, and challenges associated with treatment. For the quantitative analyses, the sample was split into two subgroups defined by treatment response: treatment responders (those who never used their primary substance again or decreased use) and treatment non-responders (those with no change or increased use). The researchers calculated means and standard deviations for questionnaire items, then compared subgroups using independent-sample t-tests and Cohen’s d effect sizes. To reduce Type I error, only items with p < .01 and effect sizes >.80 were interpreted as meaningfully different between subgroups. Analyses were performed in SPSS version 23. The qualitative component used content analysis of open-ended responses. The coding process began with reading all responses to generate potential themes, followed by refinement and operational definitions for each theme. Each theme was assigned a numeric code and participants’ comments were allocated to themes; absolute counts of coded ‘‘utterances’’ per theme were calculated. The same treatment-response grouping used in the quantitative analysis was applied to compare qualitative responses between responders and non-responders. The extracted text does not clearly report several procedural details that would be relevant for interpretation, including dosing and regimen of ibogaine, whether psychological preparation or formal integration support was provided as part of treatment, the exact timing between treatment and survey, and the psychometric properties or item content of the modified questionnaire beyond its general focus on persisting effects.

The total sample analysed was n = 73. Frequency counts of demographics, primary substance use and treatment history were conducted for the full sample; the extracted text notes that most participants were White and male but does not provide a full demographic breakdown in the supplied text. Quantitative results indicated that most participants reported positive persisting effects following ibogaine detoxification, including increased gratitude, authenticity, meaning, and appreciation for life. When comparing treatment responders versus non-responders, the researchers reported that responders endorsed greater persisting changes on several domains: improved ability to tolerate difficult or painful feelings, greater capacity to cope with stress, and reduced unhealthy anger. Responders also reported larger increases in subjective feelings of inner peace, joy, feelings of love/openheartedness, and experiences of sacredness in life. The authors specified that only questionnaire items meeting a conservative significance threshold (p < .01) and a large effect size (Cohen’s d > .80) were interpreted as meaningfully different between subgroups, but the extracted text does not provide the individual test statistics, exact p-values, means, confidence intervals, or specific effect-size values for these comparisons. Qualitative content analysis yielded themes consistent with the quantitative findings. Treatment responders more frequently reported a heightened sense of spiritual awareness and stronger intra- and interpersonal connection after ibogaine detoxification. Participants also described challenges: psychological and health-related difficulties during the treatment episode and difficulties integrating the acute effects into daily life afterwards. The extracted text does not provide detailed counts or proportions for each qualitative theme in the summary provided here, nor does it present participant-level quotations beyond the thematic descriptions.

The authors interpret their findings as evidence that ibogaine detoxification is associated with a range of persisting subjective changes and that those who achieve reductions or cessation of opioid use (treatment responders) report greater psychosocial and affective benefits. They position the results as broadly consistent with prior reports of ibogaine-associated reductions in substance use, craving and withdrawal, and with literature documenting longer-term changes in emotional, spiritual, social and health domains following psychedelic or ibogaine treatment. The researchers suggest a possible mechanism in which improvements in emotional regulation (for example, greater tolerance of painful feelings and improved coping with stress) could help sustain recovery from substance use. They also highlight increases in social and interpersonal connection after treatment and speculate that re-engagement with pre-existing social supports or the ability to form new social connections may help maintain treatment gains. The authors raise the possibility that insightful or mystical-type experiences during the ibogaine session may contribute to therapeutic outcomes, drawing an analogy to findings from psilocybin studies, and note that research using non-psychedelic congeners in animals may not capture this experiential mechanism in humans. The authors acknowledge several important limitations. The sample came from a single clinic, most participants were White males, and the response rate was 47% of all patients for whom contact information was available; therefore the findings may not generalise to other settings or populations. The data are retrospective and self-reported, so recall bias and social desirability may influence results. The authors note that attributions to ibogaine could be confounded by other aspects of the residential detoxification experience or participants’ prior treatment histories. They also used a modified measure of persisting effects whose psychometric properties were not examined in this sample, limiting confidence in the measurement. The cross-sectional, retrospective design precludes causal or temporal inferences about whether reported psychological changes led to reduced substance use or vice versa. Based on their findings and limitations, the authors recommend prospective, longitudinal, and experimental studies to clarify mechanisms and causal relationships. They advocate further qualitative and mixed-methods research to capture phenomenology and to inform theoretical models of short- and long-term outcomes. Clinically, they highlight the frequent challenge of post-treatment integration and suggest that aftercare or integration supports (for example, residential or outpatient psychological services, recovery coaching, involvement of family/significant others, mutual-support connections, or telemental health follow-up) might improve outcomes, particularly for patients with limited social support.

The authors conclude that this study, the largest published sample to date of opioid users who have undergone ibogaine detoxification, documents an array of persisting subjective benefits as well as challenges. Treatment responders reported the greatest psychosocial gains, including increases in gratitude, authenticity, meaning, positive affect, affective coping, and social connection. The authors emphasise that these findings are preliminary given methodological limitations and call for rigorous, prospective research and enhanced integration/aftercare services for patients receiving ibogaine treatment.